An economic model of haemophilia in Mexico

Haemophilia

Volumn 10, Issue 1, 2004, Pages 9-17

  Martínez Murillo, Carlos ^a   Quintana, S ^a   Ambriz, R ^a   Benitez, H ^b   Berges, A ^b   Collazo, J ^c   Esparza, A ^b   Pompa, T ^a   Taboada, C ^d   Zavala, S ^a   Larochelle, M R ^e   Bentkover, J D ^e  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b HOSPITAL DE PEDIATRÍA   (Mexico)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d Instituto de Pediatría   (Mexico)

^e Innovative Health Solutions   (United States)

Author keywords

Concentrate; Cost; Cryoprecipitate; Economics; Haemophilia; Mexico

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 CRYOPRECIPITATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTHROPATHY; CALCULATION; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HEMOPHILIA A; HEPATITIS C; HOME CARE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MEXICO; OUTCOMES RESEARCH; OUTPATIENT CARE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY ANALYSIS;

EID: 10744233957     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00811.x     Document Type: Review

References (38)

1. Aledort LM. Unsolved problems in haemophilia. Haemophilia 1998; 4: 341-5.
2. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001; 7: 117-22.
3. Kernoff P. Current Factor VIII Usage Related to Self-sufficiency: a European Overview. Factor VIII: Purity and Prophylaxis. Royal Society of Medicine Services Roundtable Series. No. 25, 1991: 4-11.
4. World Federation of Hemophilia and Hemophilia of Georgia: Protocols for the Treatment of Hemophilia and von Willebrand Disease. Treatment of Hemophilia Monograph Series, 1998; 14. Available at: http://www.wfh.org/Content_Documents/TOH_Monographs/ TOH14_Protocols_Treatment_V6.doc [accessed 3/7/02].
5. Proietti FA, Proietti AB, Costa MF et al. Exposure to acellular blood products and risk of HIV infection in hemophiliacs from Belo Horizonte, Brazil. Rev Inst Med Trop Sao Paulo 1992; 34: 227-32.
6. Coffin CM. Current issues in transfusion therapy. 1. Risks of infection. Postgrad Med 1986; 80: 219-24.
7. Brenner B, Back D, Ben-Porath E, Hazani A, Martrinowitz U, Tatarski I. Coinfection with hepatitis viruses and human immunodeficiency virus in multiply transfused patients. Isr J Med Sci 1994; 30: 886-90.
8. Evatt BL, Austin H, Leon G, Ruiz Sáez A, de Bosch N. Hemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate. Haemophilia 1999; 5: 295-300.
9. Galpin SA, Karayiannis P, Middleton SM, Thomas HC. The removal of hepatitis B virus from factor VIII concentrates by fractionation ethylene maleic anhydride polyelectrolyte. J Med Virol 1984; 14: 229-33.
10. Hepatitis Foundation International. Available at http:// www.hepfi.org 2001 [accessed 29 January, 2002].
11. Koop C. The Epidemic. Dartmouth College, 1998. Available at http://www.epidemic.org/theFacts/theEpidemic/USHealthCareCosts.html [accessed 29 January, 2002].
12. Pandav CS, Anad K, Shamanna BR, Chowdhury S, Nath LM. Economic consequences of HIV/AIDS in India. Natl Med J India 1997; 10: 27-30.
13. Total costs in the United States for treating people with HIV disease were $7 to $8 billion in 1006. Agency for Healthcare Research and Quality 2000; 241: 14-15.
14. Anand K, Pandav CS, Nath LM. Impact of HIV/AIDS on the national economy of India. Health Policy 1999; 47: 195-205.
15. Schimpf K, Mannucci PM, Kreutz W et al. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. N Engl J Med 1987; 316: 918-22.
16. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79: 3130-7.
17. Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992; 62: 193-9.
18. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Throm Haemost 2002; 87: 224-30.
19. Ekert H, Moorehead M, Williamson G. Home treatment of haemophilia. A follow-up study. Med J Aust 1981; 2: 21-23.
20. Szucs T, Öffner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia 1996; 2: 211-7.
21. Guenthner EE, Hilgartner MW, Miller CH, Vienne G. Hemophilic arthropathy: effect of home care on treatment patterns and joint disease. J Pediatr 1980; 97: 378-82.
22. Molho P, Rolland N, Lebrun T et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study. Haemophilia 2000; 6: 23-32.
23. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. Int J Technol Assess Health Care 1995; 11: 327-44.
24. Astermark J. Approaches to funding: Swedish cost-effectiveness study. Haemophilia 1998; 4(Suppl 1):10-12.
25. Pettersson H. Radiographic scores and implication. Semin Hematol 1993; 30: 7-9.
26. Gilliland BC. Relapsing Polychondrist and Other Arthritides. Harrison's Principles of Internal Medicine, 14th edn. 1959 pp.
27. Nuss R, et al. MRI findings in hemophilic joints treated with radiosynoviorthesis. Haemphilia 2000; 6: 162-9.
28. Rodringuez-Merchan EC. Articular Bleeding (Hemarthrosis) in Haemophilia, 2000. Available at http://www.wfh.org/Content_Documents/ TOH%20Monographs/TOH23_Hemarthrosis.pdf [accessed 20 September 2001].
29. Weelees CR. Wheeless' Textbook of Orthopaedics. Clinical Manifestations: Hemophilic Arthropathy. E textbook site index1/40. http://www.medmedia.com/oa4/68.htm [accessed 20 September 2001].
30. Central Intelligence Agency. CIA World Factbook, 2001. Available from http://www.cia.gov/cia/publications/factbook/index.html [accessed 29 January 2002].
31. Murray CJ, Lopez AD. Global Health Statistics. Harvard University Press on behalf of the World Health Organization and the World Bank, 1996: 906 p.
32. Pacific Exchange Rate Service: http://blacktusk.commerce.ubc.ca/cgi-bin/fxdata [accessed 2 May 2002].
33. Pollack S, Atias D, Yoffe G, Katz R, Shechter Y, Tatarski I. Impaired immune function in hemophilia patients treated exclusively with cryoprecipitate: relation to duration of treatment. Am J Hematol 1985; 20: 1-6.
34. Forsythe S, Gilks C. Economic issues and antiretroviral therapy in developing countries. Trans R Soc Trop Med Hyg 1999; 93: 1-3.
35. Toro L, Jara C, Adauy A et al. Medical care costs for HIV-positive and AIDS patients in four hospitals in Santiago, Chile. Rev Med Chil 1998; 126: 218-24.
36. Hansen K, Chapman G, Chitsike I, Kasilo O, Mwaluko G. The costs of HIV/AIDS care at government hospitals in Zimbabwe. Health Policy Plan 2000; 15: 432-40.
37. Mullins CD, Whitelaw G, Cooke JL, Beck EJ. Indirect cost of HIV infection in England. Clin Ther 2000; 22: 1333-45.
38. Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R. Cost-effectiveness of combination therapy for na patients with chronic hepatitis C. J Hepatol 2000; 33: 651-8.